Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade.
Kaneko S, Kurosaki M, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Itakura J, Takahashi Y, Nakanishi H, Asano D, Irie T, Kawachi Y, Izumi N. Kaneko S, et al. Among authors: osawa l. Hepatol Res. 2021 Aug;51(8):902-908. doi: 10.1111/hepr.13673. Epub 2021 Jun 18. Hepatol Res. 2021. PMID: 34046984
Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography.
Higuchi M, Tamaki N, Kurosaki M, Watakabe K, Osawa L, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Higuchi M, et al. Among authors: osawa l. Clin Gastroenterol Hepatol. 2019 Nov;17(12):2616-2618. doi: 10.1016/j.cgh.2018.11.046. Epub 2018 Nov 28. Clin Gastroenterol Hepatol. 2019. PMID: 30502507
Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Tamaki N, et al. Among authors: osawa l. J Viral Hepat. 2019 Jul;26(7):893-899. doi: 10.1111/jvh.13103. Epub 2019 May 3. J Viral Hepat. 2019. PMID: 30974045
Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
Kaneko S, Kurosaki M, Tamaki N, Itakura J, Hayashi T, Kirino S, Osawa L, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Yasui Y, Tsuchiya K, Nakanishi H, Takahashi Y, Watanabe M, Izumi N. Kaneko S, et al. Among authors: osawa l. J Gastroenterol Hepatol. 2019 Nov;34(11):2004-2010. doi: 10.1111/jgh.14686. Epub 2019 May 21. J Gastroenterol Hepatol. 2019. PMID: 31017689
Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease.
Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Tamaki N, et al. Among authors: osawa l. Sci Rep. 2019 Jul 12;9(1):10109. doi: 10.1038/s41598-019-46172-1. Sci Rep. 2019. PMID: 31300805 Free PMC article.
Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib.
Kaneko S, Tsuchiya K, Kurosaki M, Kirino S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Takeguchi T, Takeguchi Y, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Izumi N. Kaneko S, et al. Among authors: osawa l. Hepatol Res. 2020 Jan;50(1):137-143. doi: 10.1111/hepr.13416. Epub 2019 Sep 6. Hepatol Res. 2020. PMID: 31349377
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma.
Takada H, Kurosaki M, Tsuchiya K, Komiyama Y, Itakura J, Takahashi Y, Nakanishi H, Yasui Y, Tamaki N, Maeyashiki C, Kaneko S, Takaura K, Higuchi M, Okada M, Wang W, Osawa L, Sekiguchi S, Hayakawa Y, Yamashita K, Enomoto N, Izumi N. Takada H, et al. Among authors: osawa l. Cancers (Basel). 2019 Aug 27;11(9):1256. doi: 10.3390/cancers11091256. Cancers (Basel). 2019. PMID: 31461985 Free PMC article.
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice.
Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Wang W, et al. Among authors: osawa l. Cancers (Basel). 2019 Oct 9;11(10):1517. doi: 10.3390/cancers11101517. Cancers (Basel). 2019. PMID: 31601010 Free PMC article.
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S, Tamaki N, Kaneko S, Kurosaki M, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Yasui Y, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Izumi N. Kirino S, et al. Among authors: osawa l. J Gastroenterol Hepatol. 2020 Sep;35(9):1595-1601. doi: 10.1111/jgh.14990. Epub 2020 Feb 11. J Gastroenterol Hepatol. 2020. PMID: 31975419
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
Tamaki N, Kurosaki M, Nakanishi H, Itakura J, Inada K, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Takahashi Y, Izumi N. Tamaki N, et al. Among authors: osawa l. J Med Virol. 2020 Aug;92(8):1355-1358. doi: 10.1002/jmv.25692. Epub 2020 Feb 7. J Med Virol. 2020. PMID: 31994737
40 results